CADL
Candel Therapeutics, Inc.
Healthcare · Biotechnology · NGM
$8.51
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
MODERATE
Data Confidence: 57.1%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$632M
Total market value of the company
Trailing P/E
N/A
Forward P/E
-13.48
Based on estimated future earnings — lower means cheaper
Rev Growth
N/A
Year-over-year revenue change
Profit Margin
N/A
How much profit the company keeps from each dollar of revenue
ROE
-51.2%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$18.88
+122% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 8 analysts covering this stock
About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

https://www.candeltx.com

Country: United States Employees: 55 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
7.6% PASS
Debt must be below 33% of total assets
Cash Ratio
18.7% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
0.443
Positive but modest risk-adjusted returns
Kelly Fraction
0.0226
Modest edge detected — smaller position warranted
Calmar Ratio
-0.056
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-3.6%
Historical annualised return based on price data
Max Drawdown
-64.0%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
26
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
N/A
52W High
$9.27
8% below the year high
52W Low
$4.35
96% above the year low
Avg Volume
1,745,250
Average daily shares traded — higher means easier to buy and sell
Short Ratio
8.9
Days it would take all short sellers to cover — higher means more crowded
Short % Float
26.1%
Very high short interest — potential squeeze candidate
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.72
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.36
Conservative use of debt — low financial risk
Current Ratio
28.05
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
27.63
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Free Cash Flow
$-39,041,876
Negative — the business is spending more than it generates
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
$-54,422,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
8
Target High
$26.00
Target Median
$18.88
Target Low
$7.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-02-23 MANNING PAUL B. Director 550,458 $2,999,996
2025-07-28 NICHOLS WILLIAMS GARRETT Officer 937 $6,540
2025-07-28 NICHOLS WILLIAMS GARRETT Officer 937 $1,209
2025-06-30 NICHOLS WILLIAMS GARRETT Officer 781 $3,936
2025-06-30 NICHOLS WILLIAMS GARRETT Officer 781 $1,007
2025-06-25 PAPA JOSEPH C Director 64,239 $299,996
2025-06-25 MANNING PAUL B. Director 1,070,663 $4,999,996
2025-06-25 NABEL GARY J. Director 5,353 $24,999
2025-06-25 MARTELL CHRISTOPHER Director 111,349 $520,000
2025-06-25 TAK PAUL PETER Chief Executive Officer 42,826 $199,997
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.